What is the ELF (Enhanced Liver Fibrosis) test and how is it used to evaluate liver fibrosis?

What is ELF Testing?

The Enhanced Liver Fibrosis (ELF) test is a proprietary blood-based biomarker panel that measures three serum markers of hepatic extracellular matrix metabolism—hyaluronic acid, procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1)—combined through a logarithmic algorithm to generate a score that reflects the severity of liver fibrosis. 1, 2

Clinical Purpose and Application

The ELF test serves as a noninvasive alternative to liver biopsy for assessing liver fibrosis severity in patients with chronic liver disease, particularly in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) 1, 3. The test is recommended by the American Gastroenterological Association as a secondary risk assessment tool when elastography is unavailable, or as part of a two-step diagnostic strategy following initial screening with simpler biomarkers like FIB-4. 1

Diagnostic Performance

Fibrosis Stage Correlation

• ELF scores increase progressively with advancing fibrosis stages: median scores are approximately 8.7 for F0, 9.3 for F1, 10.1 for F2, 10.7 for F3, and 12.0 for F4 (cirrhosis) 4
• The test demonstrates area under the receiver operating characteristic curve (AUROC) values of 0.802-0.829 for detecting advanced fibrosis (F3-4) across multiple studies 4, 3, 5

Key Cutoff Values

• Low cutoff (9.8): Provides high sensitivity (90-91%) and excellent negative predictive value (>96%) for ruling out advanced fibrosis 4, 6
• High cutoff (10.83): Provides high specificity (90-93%) for ruling in advanced fibrosis 4, 7
• Very high scores (≥13): Indicate particularly high-risk patients with 26% decompensation rate within 90 days and 38% all-cause mortality at 1 year 8

Advantages Over Other Noninvasive Tests

Superior to FIB-4 in Specific Populations

• ELF outperforms FIB-4 for detecting cirrhosis (F4) and maintains accuracy regardless of patient age 4
• In patients with type 2 diabetes mellitus, ELF (AUROC 0.820) significantly outperforms both FIB-4 (AUROC 0.698) and NAFLD Fibrosis Score (AUROC 0.700), addressing a critical unmet need since diabetes impairs the accuracy of age-dependent scores 6
• ELF provides better short-term prognostication for liver-related mortality compared to FIB-4, particularly within 6 months (AUROC 94.3% vs 82.8%) 8

Age Independence

• Unlike FIB-4, which increases with age regardless of fibrosis stage, ELF scores remain stable across age groups for the same fibrosis stage 4
• This makes ELF particularly valuable in elderly populations with chronic liver disease 4

Two-Step Diagnostic Strategy

The AASLD-recommended approach combines FIB-4 as first-line screening followed by ELF testing for indeterminate results, optimizing diagnostic accuracy while minimizing unnecessary liver biopsies. 1, 3

Sequential Testing Algorithm

• Step 1: Use FIB-4 ≥1.30 as initial screen 3
• Step 2: Apply ELF ≥9.8 to FIB-4-positive patients 3
• This combination achieves 67.9% sensitivity, 90.4% specificity, and excludes 71.8% of patients from unnecessary liver biopsies 3

Alternative Combinations

• FIB-4 (cutoff 2.67) followed by ELF (cutoff 9.34): Increases sensitivity to 95.9% for advanced fibrosis detection 7
• ELF combined with liver stiffness measurement: Increases specificity to 97.9% when both tests are positive 7

Prognostic Value

ELF scores predict not only fibrosis stage but also clinical outcomes including hepatic decompensation and mortality. 8

• Each 1-unit increase in ELF score associates with increased risk of decompensation (adjusted HR 2.215) and liver-related mortality (adjusted HR 2.024) 8
• ELF identifies patients at increased risk of progression to cirrhosis and liver-related clinical events 1

Clinical Implementation

Referral Optimization

• Adding ELF as a second-line test reduces specialist hepatology referrals by 34% while maintaining safety 8
• The test is useful across primary, secondary, and tertiary care settings for risk stratification 2

Urgent Assessment Triggers

• Patients with ELF ≥13 require urgent clinical assessment due to extremely high short-term risk of decompensation and mortality 8

Common Pitfalls to Avoid

• Do not use ELF as a standalone first-line test; it is most cost-effective when used sequentially after simpler biomarkers like FIB-4 1, 3
• Do not ignore very high ELF scores (≥13) as these patients need immediate specialist evaluation 8
• Remember that ELF is proprietary and requires specific laboratory capabilities, unlike freely calculated scores such as FIB-4 1